NLS Pharma Group this week announced that it has begun enrollment
for its Phase II clinical trial for Mazindol, which will be conducted on adults
with DSM-5 Attention Deficit Hyperactivity Disorder (ADHD).
The trial will be
double-blind, placebo-controlled and test the efficiency, safety, patient
tolerability and pharmacokinetics of NLS’s Controlled Release (CR) Formulation of Mazindol.
"The first patient in marks an important milestone in
the development of a non-amphetaminic stimulant for ADHD," NLS Pharma
Group CEO Alex Zwyer said.
"As only a fraction of adults with ADHD are being
treated with traditional stimulants, it is clear that alternatives are needed,”
Dr. Tim Wigal, lead investigator, said. “ADHD can affect numerous
aspects of a patient's life and the current Phase II study is examining
functional outcomes in order to determine the impact of treatment. Depending on
the results in adults, this line of research may quickly expand to include
younger patients."
NLS announces patient enrollment in Mazindol trial
Alerts Sign-up